<DOC>
	<DOCNO>NCT02129192</DOCNO>
	<brief_summary>To investigate steady state pharmacokinetics different formulation Telmisartan , Amlodipine , Hydrochlorothiazide ( HCTZ ) .</brief_summary>
	<brief_title>Bioequivalence Study Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg ( T80/A5/H12.5 mg ) Fixed-dose Combination ( FDC ) Tablet T80/H12.5 mg Tab A5 mg ( Encap A2.5 mg Tab x2 ) Concomitant Use</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject age &gt; =20 &lt; =35 year ; body weight : &gt; =50 kg &lt; =80 kg ; body mass index : &gt; =18.0 &lt; =25.0 kg/m2 Without clinically significant finding complication basis complete medical history , include physical examination , vital sign ( blood pressure ( BP ) , pulse rate ( PR ) , body temperature ) Signed date write informed consent prior admission trial accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : Any find medical examination ( include BP , PR ECGs ) deviate normal clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>